masld glp 1 Beyond glucagon-like peptide-1: The promise of polyagonists in metabolic dysfunction–associated steatotic liver disease and metabolic dysfunction–associated steatohepatitis—A systematic review of randomized trials The Emerging Role of Glucagon-Like

BMJ Open Diabetes Res Care 10(6):e002995 Jermendy G, Kiss Z, Rokszin G, Abonyi-Tth Z, Lengyel C, Kempler P et al (2022) Changing patterns of antihyperglycaemic treatment among patients with type 2 diabetes in Hungary between 2015 and 2020-nationwide data from a register-based analysis

Protein oats work in any application that uses traditional oats, allowing manufacturers to increase nutrient-density without affecting the taste or texture consumers expect

Benoit SC, Clegg DJ, Seeley RJ, Woods SC

Dennis Bruemmer (Cardiologist and Director of the Center for Cardiometabolic Health in the section of Preventive Cardiology at the Cleveland Clinic)

Eli Lilly and Novo Nordisk have had multiple FDA-approved GLP-1 drugs on the market since 2022, though record-high demand, chronic supply shortages and pricing concerns have created challenges for the drugmakers

We need to distinguish science-based solutions from marketing hype. Meet the experts : Dendy Engelman, MD, is a New York City-based dermatologist and director of dermatologic surgery at Metropolitan Hospital